Abstract
It appears that the presence of a mutation of the PIGA gene alone is not sufficient for the development of paroxysmal nocturnal hemoglobinuria (PNH) and that concomitant expansion of PIGA-mutant clones is indispensable; however, the mechanism of such expansion is not yet fully elucidated. Because of the close association between idiopathic aplastic anemia and PNH, the prevailing hypothesis is that PNH progenitor cells can survive rather than normal progenitor cells against autoimmune attack on bone marrow cells by evading immune recognition with the aid of their membrane characteristics, leading to selective expansion of PNH clones. Various attempts have so far been made to prove this hypothesis, including examining the apoptosis resistance of PNH hematopoietic cells, involvement of conventional cytotoxic T cells or certain T-cell subsets such as CD1d-restricted T cells and natural killer receptor-expressing T cells as the immune effector cells, and involvement of natural killer cells under some stress situations. In this chapter, the results of these studies will be outlined; we will also refer to our own findings on the relationship between NKG2D-mediated immunity and the clonal selection of PNH cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hill A, Richards SJ, Hillmen P (2007) Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol 137 (3):181–192. doi: BJH6554 [pii] 10.1111/j.1365-2141.2007.06554.x
Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L (1999) Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A 96(9):5209–5214
Rosti V, Tremml G, Soares V, Pandolfi PP, Luzzatto L, Bessler M (1997) Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion. J Clin Invest 100(5):1028–1036. doi:10.1172/JCI119613
Parker CJ (2002) Historical aspects of paroxysmal nocturnal haemoglobinuria: ‘defining the disease’. Br J Haematol 117 (1):3–22. doi:3374 [pii]
Horikawa K, Fujisao S, Iwamoto N, Nagakura S, Kawaguchi T, Nishimura Y, Takatsuki K, Nakakuma H (1996) Cyclosporin-responsive pancytopenia and HLA class II alleles of a patient with paroxysmal nocturnal hemoglobinuria. Int J Hematol 63(2):165–166
Maciejewski JP, Follmann D, Nakamura R, Saunthararajah Y, Rivera CE, Simonis T, Brown KE, Barrett JA, Young NS (2001) Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 98(13):3513–3519
Shichishima T, Okamoto M, Ikeda K, Kaneshige T, Sugiyama H, Terasawa T, Osumi K, Maruyama Y (2002) HLA class II haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood 100(1):22–28
Risitano AM, Maciejewski JP, Muranski P, Wlodarski M, O’Keefe C, Sloand EM, Young NS (2005) Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients. Leukemia 19(2):217–222
Karadimitris A, Manavalan JS, Thaler HT, Notaro R, Araten DJ, Nafa K, Roberts IA, Weksler ME, Luzzatto L (2000) Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood 96(7):2613–2620
Risitano AM, Kook H, Zeng W, Chen G, Young NS, Maciejewski JP (2002) Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V beta CDR3 spectratyping and flow cytometry. Blood 100(1):178–183
Coluzzi S, Biffoni M, Pasqualetti D, Perrone MP, Vaglio S, Rahimi H, Arista MC, Laurenti L, Cerretti R, Girelli G (2004) Production of interferon-gamma by lymphocytes from paroxysmal nocturnal haemoglobinuria patients: relationship with clinical status. Br J Haematol 124(5):685–690
Brodsky RA, Vala MS, Barber JP, Medof ME, Jones RJ (1997) Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A 94(16):8756–8760
Horikawa K, Nakakuma H, Kawaguchi T, Iwamoto N, Nagakura S, Kagimoto T, Takatsuki K (1997) Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome. Blood 90(7):2716–2722
Ware RE, Nishimura J, Moody MA, Smith C, Rosse WF, Howard TA (1998) The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria. Blood 92(7):2541–2550
Chen R, Nagarajan S, Prince GM, Maheshwari U, Terstappen LW, Kaplan DR, Gerson SL, Albert JM, Dunn DE, Lazarus HM, Medof ME (2000) Impaired growth and elevated fas receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglobinuria. J Clin Invest 106(5):689–696. doi:10.1172/JCI8328
Chen G, Kirby M, Zeng W, Young NS, Maciejewski JP (2002) Superior growth of glycophosphatidylinositol-anchored protein-deficient progenitor cells in vitro is due to the higher apoptotic rate of progenitors with normal phenotype in vivo. Exp Hematol 30(7):774–782. doi: S0301472X02008111 [pii]
Chen G, Zeng W, Maciejewski JP, Kcyvanfar K, Billings EM, Young NS (2005) Differential gene expression in hematopoietic progenitors from paroxysmal nocturnal hemoglobinuria patients reveals an apoptosis/immune response in ‘normal’ phenotype cells. Leukemia 19(5):862–868. doi:10.1038/sj.leu.2403678
Maciejewski J, Selleri C, Anderson S, Young NS (1995) Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85(11):3183–3190
Young NS, Maciejewski J (1997) The pathophysiology of acquired aplastic anemia. N Engl J Med 336(19):1365–1372. doi:10.1056/NEJM199705083361906
Barcellini W, Fermo E, Guia Imperiali F, Zaninoni A, Bianchi P, Boschetti C, Zanella A (2004) Increased resistance of PIG-A- bone marrow progenitors to tumor necrosis factor a and interferon gamma: possible implications for the in vivo dominance of paroxysmal nocturnal hemoglobinuria clones. Haematologica 89(6):651–656
Szpurka H, Schade AE, Jankowska AM, Maciejewski JP (2008) Altered lipid raft composition and defective cell death signal transduction in glycosylphosphatidylinositol anchor-deficient PIG-A mutant cells. Br J Haematol 142(3):413–422. doi:10.1111/j.1365-2141.2008.07203.x
Kulkarni S, Bessler M (2003) Effect of proinflammatory cytokines on PIGA- hematopoiesis. Exp Hematol 31(9):770–778
Young NS, Calado RT, Scheinberg P (2006) Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108(8):2509–2519. doi:10.1182/blood-2006-03-010777
Karadimitris A, Notaro R, Koehne G, Roberts IA, Luzzatto L (2000) PNH cells are as sensitive to T-cell-mediated lysis as their normal counterparts: implications for the pathogenesis of paroxysmal nocturnal haemoglobinuria. Br J Haematol 111(4):1158–1163
Hirano N, Butler MO, Von Bergwelt-Baildon MS, Maecker B, Schultze JL, O’Connor KC, Schur PH, Kojima S, Guinan EC, Nadler LM (2003) Autoantibodies frequently detected in patients with aplastic anemia. Blood 102(13):4567–4575. doi:10.1182/blood-2002-11-3409
Feng X, Chuhjo T, Sugimori C, Kotani T, Lu X, Takami A, Takamatsu H, Yamazaki H, Nakao S (2004) Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 104(8):2425–2431. doi:10.1182/blood-2004-05-1839
Kinoshita T, Inoue N (2002) Relationship between aplastic anemia and paroxysmal nocturnal hemoglobinuria. Int J Hematol 75(2):117–122
Murakami Y, Kosaka H, Maeda Y, Nishimura J, Inoue N, Ohishi K, Okabe M, Takeda J, Kinoshita T (2002) Inefficient response of T lymphocytes to glycosylphosphatidylinositol anchor-negative cells: implications for paroxysmal nocturnal hemoglobinuria. Blood 100(12):4116–4122
Nowak J, Wozniak J, Mendek-Czajkowska E, Dlugokecka A, Mika-Witkowska R, Rogatko-Koros M, Graczyk-Pol E, Marosz-Rudnicka A, Dziopa J, Golec A, Kopec-Szlezak J, Warzocha K (2013) Potential link between MHC-self-peptide presentation and hematopoiesis; the analysis of HLA-DR expression in CD34-positive cells and self-peptide presentation repertoires of MHC molecules associated with paroxysmal nocturnal hemoglobinuria. Cell Biochem Biophys 65(3):321–333. doi:10.1007/s12013-012-9435-1
Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, Maciejewski JP, Loughran TP Jr (2012) Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leuk Res 36(5):581–587. doi:10.1016/j.leukres.2012.02.001
Ikeda K, Shichishima T, Yasukawa M, Nakamura-Shichishima A, Noji H, Akutsu K, Osumi K, Maruyama Y (2007) The role of Wilms’ tumor gene peptide-specific cytotoxic T lymphocytes in immunologic selection of a paroxysmal nocturnal hemoglobinuria clone. Exp Hematol 35(4):618–626
Karadimitris A, Luzzatto L (2001) The cellular pathogenesis of paroxysmal nocturnal haemoglobinuria. Leukemia 15(8):1148–1152
Brennan PJ, Brigl M, Brenner MB (2013) Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 13(2):101–117. doi:10.1038/nri3369
Gargiulo L, Papaioannou M, Sica M, Talini G, Chaidos A, Richichi B, Nikolaev AV, Nativi C, Layton M, de la Fuente J, Roberts I, Luzzatto L, Notaro R, Karadimitris A (2013) Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. Blood 121(14):2753–2761. doi:10.1182/blood-2012-11-469353
van Bergen J, Koning F (2010) The tortoise and the hare: slowly evolving T-cell responses take hastily evolving KIR. Immunology 131(3):301–309. doi:10.1111/j.1365-2567.2010.03337.x
Poggi A, Negrini S, Zocchi MR, Massaro AM, Garbarino L, Lastraioli S, Gargiulo L, Luzzatto L, Notaro R (2005) Patients with paroxysmal nocturnal hemoglobinuria have a high frequency of peripheral-blood T cells expressing activating isoforms of inhibiting superfamily receptors. Blood 106(7):2399–2408
van Bijnen ST, Withaar M, Preijers F, van der Meer A, de Witte T, Muus P, Dolstra H (2011) T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines. Exp Hematol 39(7):751–762 e751–753. doi:S0301-472X(11)00176-7 [pii] 10.1016/j.exphem.2011.04.003
Nagakura S, Ishihara S, Dunn DE, Nishimura J, Kawaguchi T, Horikawa K, Hidaka M, Kagimoto T, Eto N, Mitsuya H, Kinoshita T, Young NS, Nakakuma H (2002) Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro. Blood 100(3):1031–1037
Hanaoka N, Kawaguchi T, Horikawa K, Nagakura S, Mitsuya H, Nakakuma H (2006) Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP. Blood 107(3):1184–1191
Raulet DH, Gasser S, Gowen BG, Deng W, Jung H (2013) Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 31:413–441. doi:10.1146/annurev-immunol-032712-095951
Hanaoka N, Nakakuma H, Horikawa K, Nagakura S, Tsuzuki Y, Shimanuki M, Kojima K, Yonemura Y, Kawaguchi T (2009) NKG2D-mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes. Br J Haematol 146(5):538–545. doi:BJH7795 [pii] 10.1111/j.1365-2141.2009.07795.x
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Japan KK
About this chapter
Cite this chapter
Kawaguchi, T., Nakakuma, H. (2017). Pathogenesis of Clonal Dominance in PNH: Selection Mechanisms in PNH. In: Kanakura, Y., Kinoshita, T., Nishimura, Ji. (eds) Paroxysmal Nocturnal Hemoglobinuria. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56003-6_13
Download citation
DOI: https://doi.org/10.1007/978-4-431-56003-6_13
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-56001-2
Online ISBN: 978-4-431-56003-6
eBook Packages: MedicineMedicine (R0)